Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
KG5
Cat. No.:
0225LY-0768
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
KG5 functions as a dual allosteric inhibitor of B-Raf and PDGFR-beta (Kd: 520 nM) while also targeting KIT, FLT3, and c-Raf for antiangiogenic and anticancer effects.
Synonym:
877874-85-6; 2-(Methylthio)-6-[4-(5-{[3-(trifluoromethyl)phenyl]amino}-4H-1,2,4-triazol-3-yl)-phenoxy]-pyrimidin-4-amine; 2-(Methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-4-pyrimidinamine
CAS No.:
877874-85-6
Compound CID:
53328059
Formula:
C20H16F3N7OS
Formula Weight:
459.45
Specification
Targets&IC50:
c-Kit: 170 nM (Kd); FLT3: 52 nM (Kd); PDGFRα: 300 nM (Kd); PDGFRβ: 520 nM (Kd)
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
KG5 can be used in angiogenesis studies to explore the disruption of VEGF-mediated signaling through the inhibition of PDGFR beta.
Library Information
Target:
Raf; FLT; PDGFR; c-Kit
Receptor:
B-Raf; C-Raf; PDGFRβ; FLT3; c-Kit; PDGFRα
Pathways:
Tyrosine kinase/adaptors; MAPK; Angiogenesis
Plate Number:
AOCL-10
Plate Location:
h6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
95 mg/mL; 206.77 mM
